Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Hepatocellular carcinoma

(2021) Josep M. Llovet et al.   Nature Reviews Disease Primers

The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma

(2021) Philippe Merle   Cancers

Checkpoint Inhibitors and Hepatotoxicity

(2021) Stephen D. H. Malnick et al.   Biomedicines

Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies

(2021) Xiufeng Liu et al.   Future Oncology

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

(2021) Dominik Pfister et al.   NATURE

Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH

(2021) Michael Dudek et al.   NATURE

Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma

(2020) Haijing Deng et al.   Liver Cancer

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events

(2020) Hideki Iwamoto et al.   Cancers

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

(2020) Shigeo Shimose et al.   Cancers

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

(2020) Masatoshi Kudo   Liver Cancer

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Immune checkpoint inhibitors for hepatocellular carcinoma

(2019) Imane El Dika et al.   CANCER

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Management of Hepatocellular Carcinoma in Japan: Current Trends

(2019) Masatoshi Kudo   Liver Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

(2018) Florentia Dimitriou et al.   JOURNAL OF IMMUNOTHERAPY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Systemic Therapy for Hepatocellular Carcinoma: Latest Advances

(2018) Masatoshi Kudo   Cancers

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma

(2017) Jianhua Liu et al.   ONCOLOGY REPORTS

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

(2015) Philip J. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

How to Improve Treatment Outcomes for Hepatocellular Carcinoma of Intermediate and Advanced Stage

(2012) Do Young Kim et al.   DIGESTIVE DISEASES

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE